Article ; Online: Ligand-installed polymeric nanocarriers for combination chemotherapy of EGFR-positive ovarian cancer.
Journal of controlled release : official journal of the Controlled Release Society
2023 Volume 360, Page(s) 872–887
Abstract: Combination chemotherapeutic drugs administered via a single nanocarrier for cancer treatment provides benefits in reducing dose-limiting toxicities, improving the pharmacokinetic properties of the cargo and achieving spatial-temporal synchronization of ... ...
| Abstract | Combination chemotherapeutic drugs administered via a single nanocarrier for cancer treatment provides benefits in reducing dose-limiting toxicities, improving the pharmacokinetic properties of the cargo and achieving spatial-temporal synchronization of drug exposure for maximized synergistic therapeutic effects. In an attempt to develop such a multi-drug carrier, our work focuses on functional multimodal polypeptide-based polymeric nanogels (NGs). Diblock copolymers poly (ethylene glycol)-b-poly (glutamic acid) (PEG-b-PGlu) modified with phenylalanine (Phe) were successfully synthesized and characterized. Self-assembly behavior of the resulting polymers was utilized for the synthesis of NGs with hydrophobic domains in cross-linked polyion cores coated with inert PEG chains. The resulting NGs were small (ca. 70 nm in diameter) and were able to encapsulate the combination of drugs with different physicochemical properties such as cisplatin and neratinib. Drug combination-loaded NGs exerted a selective synergistic cytotoxicity towards EGFR overexpressing ovarian cancer cells. Moreover, we developed ligand-installed EGFR-targeted NGs and tested them as an EGFR-overexpressing tumor-specific delivery system. Both in vitro and in vivo, ligand-installed NGs displayed preferential associations with EGFR (+) tumor cells. Ligand-installed NGs carrying cisplatin and neratinib significantly improved the treatment response of ovarian cancer xenografts. We also confirmed the importance of simultaneous administration of the dual drug combination via a single NG system which provides more therapeutic benefit than individual drug-loaded NGs administered at equivalent doses. This work illustrates the potential of our carrier system to mediate efficient delivery of a drug combination to treat EGFR overexpressing cancers. |
|---|---|
| MeSH term(s) | Female ; Humans ; Antineoplastic Agents/therapeutic use ; Cell Line, Tumor ; Cisplatin ; Drug Carriers/chemistry ; Drug Therapy, Combination ; ErbB Receptors ; Ligands ; Nanogels ; Nanoparticles/chemistry ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Polyethylene Glycols/chemistry ; Polymers/chemistry ; Animals |
| Chemical Substances | Antineoplastic Agents ; Cisplatin (Q20Q21Q62J) ; Drug Carriers ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1) ; Ligands ; Nanogels ; Polyethylene Glycols (3WJQ0SDW1A) ; Polymers |
| Language | English |
| Publishing date | 2023-07-26 |
| Publishing country | Netherlands |
| Document type | Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 632533-6 |
| ISSN | 1873-4995 ; 0168-3659 |
| ISSN (online) | 1873-4995 |
| ISSN | 0168-3659 |
| DOI | 10.1016/j.jconrel.2023.07.033 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2055: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.